Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Gonzaga, Isabela Martins ^a   Soares Lima, Sheila Coelho ^a   de Santos, Paulo Thiago Souza ^a   Blanco, Tania Cristina Moita ^b   de Reis, Bruno Souza Bianchi ^a   Quintella, Danielle Carvalho ^a   de Oliveira, Ivanir Martins ^a   de Faria, Paulo Antonio Silvestre ^a   Kruel, Cleber Dario Pinto ^c   Andreollo, Nelson Adami ^d   de Simão, Tatiana Almeida ^a,b   Pinto, Luis Felipe Ribeiro ^a,b  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^d UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

BRAF; EGFR; Esophageal cancer; HER2; KRAS; Target therapy

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BRAF GENE; CODON; CONTROLLED STUDY; EGFR GENE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS MUCOSA; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; HER2 GENE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DNA MUTATIONAL ANALYSIS; ESOPHAGEAL NEOPLASMS; FEMALE; GENES, ERBB-1; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84870322359     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-569     Document Type: Article

References (45)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917. 10.1002/ijc.25516, 21351269.
2. American Cancer Society Global cancer facts and figures 2011, Atlanta, American Cancer Society.
3. McLarty AJ, Deschamps C, Trastek VF, Allen MS, Pairolero PC, Harmsen WS. Esophageal resection for cancer of the esophagus: long-term function and quality of life. Ann Thorac Surg 1997, 63(6):1568-1572. 10.1016/S0003-4975(97)00125-2, 9205149.
4. Allen JW, Richardson JD, Edwards MJ. Squamous cell carcinoma of the esophagus: a review and update. Surg Oncol 1997, 6:193-200. 10.1016/S0960-7404(98)00003-6, 9775405.
5. Benson JD, Chen YN, Cornell-Kennon SA, Dorsch M, Kim S, Leszczyniecka M, Sellers WR, Lengauer C. Validating cancer drug target. Nature 2006, 441:451-456. 10.1038/nature04873, 16724057.
6. Baselga J. Targeting the epidermal growth factor receptor: a clinical reality. J Clin Oncol 2001, 19(Suppl 18):41S-44S.
7. Gridelli C, De Marinis F, Di Maio M, Cortinovis D, Cappuzzo F, Mok T. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. Lung Cancer 2011, 71(3):249-257. 10.1016/j.lungcan.2010.12.008, 21216486.
8. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360(14):1408-1417. 10.1056/NEJMoa0805019, 19339720.
9. Wong WM. Drug update: trastuzumab: anti-HER2 antibody for treatment of metastatic breast cancer. Cancer Pract 1999, 7(1):48-50. 10.1046/j.1523-5394.1999.07108.x, 9893005.
10. Sergina NV, Moasser MM. The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med 2007, 13(12):527-534. 10.1016/j.molmed.2007.10.002, 3035105, 17981505.
11. Jiang BH, Liu LZ. PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim Biophys Acta 2008, 1784(1):150-158. 10.1016/j.bbapap.2007.09.008, 17964232.
12. Quesnelle KM, Boehm AL, Grandis JR. STAT-mediated EGFR signaling in cancer. J Cell Biochem 2007, 102(2):311-319. 10.1002/jcb.21475, 17661350.
13. Molina JR, Adjei AA. The Ras/Raf/MAPK pathway. J Thorac Oncol 2006, 1(1):7-9. 10.1097/01243894-200601000-00004, 17409820.
14. Sebastian S, Settleman J, Reshkin SJ, Azzariti A, Bellizzi A, Paradiso A. The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim Biophys Acta 2006, 1766(1):120-139.
15. Morgan S, Grandis JR. ErbB receptors in the biology and pathology of the aerodigestive tract. Exp Cell Res 2009, 315(4):572-582. 10.1016/j.yexcr.2008.08.009, 2657476, 18778701.
16. Sequist LV, Joshi VA, Jänne PA, Bell DW, Fidias P, Lindeman NI, Louis DN, Lee JC, Mark EJ, Longtine J, Verlander P, Kucherlapati R, Meyerson M, Haber DA, Johnson BE, Lynch TJ. Epidermal growth factor receptor mutation testing in the care of lung cancer patient. Clin Cancer Res 2006, 12(14 Pt 2):4403s-4408s.
17. Press MF, Sauter G, Bernstein L, Villalobos IE, Mirlacher M, Zhou JY, Wardeh R, Li YT, Guzman R, Ma Y, Sullivan-Halley J, Santiago A, Park JM, Riva A, Slamon DJ. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 2005, 11(18):6598-6607. 10.1158/1078-0432.CCR-05-0636, 16166438.
18. Lorenzen S, Lordick F. How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer?. Curr Opin Oncol 2011, 23(4):396-402. 10.1097/CCO.0b013e3283469567, 21505336.
19. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008, 26(35):5705-5712. 10.1200/JCO.2008.18.0786, 19001320.
20. Sambrook J, Russell D. Preparation and analysis of eukaryotic genomic DNA 2001, 6.1-6.64. New York: Cold Spring Harbor Laboratory, 3rd, Molecular Cloning - A laboratory Manual, Volume 1.
21. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16(3):1215. 10.1093/nar/16.3.1215, 334765, 3344216.
22. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H. EGF receptor gene mutations are common in lung cancers from " never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci 2004, 101(3):13306-13311. 10.1073/pnas.0405220101, 516528, 15329413.
23. Robottom Ferreira AB, Ribeiro Pinto LF, Albano RM. An optimized reverse transcription-polymerase chain reaction procedure for the amplification of low copy Cyp2a3 mRNA in rat esophagus. Anal Biochem 2003, 319(2):323-326. 10.1016/S0003-2697(03)00293-8, 12871729.
24. Dimou A, Agarwal S, Anagnostou V, Viray H, Christensen S, Gould Rothberg B, Zolota V, Syrigos K, Rimm DL. Standardization of epidermal growth factor receptor (EGFR) measurement by quantitative immunofluorescence and impact on antibody-based mutation detection in non-small cell lung cancer. Am J Pathol 2011, 179(2):580-589. 10.1016/j.ajpath.2011.04.031, 3157192, 21722621.
25. Selvarajan S, Bay BH, Chng MJ, Tan PH. The HercepTest and routine C-erbB2 immunohistochemistry in breast cancer: any difference?. Ann Acad Med Singapore 2004, 33(4):473-476.
26. Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, de Marinis F, Eberhardt WE, Paz-Ares L, Störkel S, Schumacher KM, von Heydebreck A, Celik I, O'Byrne KJ. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012, 13(1):33-42. 10.1016/S1470-2045(11)70318-7, 22056021.
27. Cohen J. Statistical power analysis for the behavioral sciences 1988, New Jersey: Lawrence Erlbaum Associates.
28. Sharafinski ME, Ferris RL, Ferrone S, Grandis JR. Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck 2010, 32(10):1412-1421. 10.1002/hed.21365, 2946515, 20848399.
29. Mir MM, Dar NA, Salam I, Shah ZA. Mutations in epidermal growth factor receptor gene in esophageal squamous cell carcinoma patients in kashmir- a high incidence area of India. Int J Health Sci 2008, 2(2):17-25.
30. Sunpaweravong P, Suwiwat S, Sunpaweravong S, Puttawibul P, Mitarnun W. Correlation of epidermal growth factor receptor mutation, immunohistochemistry, and fluorescence in situ hybridization in esophageal squamous cell carcinoma. J Med Assoc Thai 2009, 92(9):1136-1142.
31. Liu QW, Fu JH, Luo KJ, Yang HX, Wang JY, Hu Y, Yang H, Bella E. Identification of EGFR and KRAS mutations in Chinese patients with esophageal squamous cell carcinoma. Dis Esophagus in press.
32. Italiano A, Follana P, Caroli FX, Badetti JL, Benchimol D, Garnier G, Gugenheim J, Haudebourg J, Keslair F, Lesbats G, Lledo G, Roussel JF, Pedeutour F, François E. Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number. Ann Surg Oncol 2008, 15(2):649-654. 10.1245/s10434-007-9667-2, 17987340.
33. Scartozzi M, Bearzi I, Mandolesi A, Pierantoni C, Loupakis F, Zaniboni A, Negri F, Quadri A, Zorzi F, Galizia E, Berardi R, Biscotti T, Labianca R, Masi G, Falcone A, Cascinu S. Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. BMC Cancer 2009, 9:303. 10.1186/1471-2407-9-303, 3087339, 19712476.
34. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouché O, Reid J, Stone S, Penault-Llorca F. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009, 27(35):5924-5930. 10.1200/JCO.2008.21.6796, 19884556.
35. Berardi R, Onofri A, Pistelli M, Maccaroni E, Scartozzi M, Pierantoni C, Cascinu S. Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer. Core Evid 2010, 5:61-76. 2963923, 21042543.
36. Laurent-Puig P, Lievre A, Blons H. Mutations and response to epidermal growth factor receptor inhibitors. Clin Cancer Res 2009, 15(4):1133-1139. 10.1158/1078-0432.CCR-08-0905, 19228718.
37. Weber A, Langhanki L, Sommerer F, Markwarth A, Wittekind C, Tannapfel A. Mutations of the BRAF gene in squamous cell carcinoma of the head and neck. Oncogene 2003, 22(30):4757-4759. 10.1038/sj.onc.1206705, 12879021.
38. Hanawa M, Suzuki S, Dobashi Y, Yamane T, Kono K, Enomoto N, Ooi A. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer 2006, 118(5):1173-1180. 10.1002/ijc.21454, 16161046.
39. Hollstein MC, Peri L, Mandard AM, Welsh JA, Montesano R, Metcalf RA, Bak M, Harris CC. Genetic analysis of human esophageal tumors from two high incidence geographic areas: frequent p53 base substitutions and absence of ras mutation. Cancer Res 1991, 51:4102-4106.
40. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008, 19(9):1523-1529. 10.1093/annonc/mdn169, 18441328.
41. Croxtall JD, McKeage K. Trastuzumab: in HER2-positive metastatic gastric cancer. Drugs 2010, 70(17):2259-2267. 10.2165/11205900-000000000-00000, 21080742.
42. Sato-Kuwabara Y, Neves JI, Fregnani JH, Sallum RA, Soares FA. Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry. BMC Cancer 2009, 9:6. 10.1186/1471-2407-9-6, 2648997, 19128465.
43. Zhan N, Dong WG, Tang YF, Wang ZS, Xiong CL. Analysis of HER2 gene amplification and protein expression in esophageal squamous cell carcinoma. Med Oncol 2012, 29(2):933-940. 10.1007/s12032-011-9850-y, 21318736.
44. Yarden Y. The EGFR family and its ligands in human cancer: signaling mechanisms and therapeutic opportunities. Eur J Cancer 2001, 37(Suppl 4):S3-S8.
45. Kim SH, Nakagawa H, Navaraj A, Naomoto Y, Klein-Szanto AJ, Rustgi AK, El-Deiry WS. Tumorigenic conversion of primary human esophageal epithelial cells using oncogene combinations in the absence of exogenous Ras. Cancer Res 2006, 66(21):10415-10424. 10.1158/0008-5472.CAN-06-2104, 17079462.